The present invention provides patients having epilepsy with a treatmentregime whereby administration of an inhibitor of PSD-95, which inhibitsbinding of aPDZ-binding ligand to a PDZ domain of PSD-95, takes place at least one houraftertermination of an episode of epilepsy. The present invention also providesspecific inhibitorsof PSD-95, namely Tat-NR2B9c(SDV) (SEQ ID NO:10), Tat-NR2B9c(TDV) (SEQ IDNO:8)or F-TatNR2B9c(SDV) (SEQ ID NO:46), for treating epilepsy, wherein the aminoacids ofthe inhibitor are natural amino acids.